Related Experiment Video
Updated: Jun 17, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Acute Disseminated Encephalomyelitis in Children and Adolescents: A Multicenter Retrospective Study of Relapse and
Seda Kanmaz1, Sanem Yılmaz1, Nihal Olgaç Dündar2
1Faculty of Medicine, Department of Pediatric Neurology, Ege University, Izmir, Turkey.
Insights
This study on acute disseminated encephalomyelitis found that anti-myelin oligodendrocyte glycoprotein antibody status did not impact relapse risk or recovery. Certain initial symptoms predict outcomes in pediatric ADEM patients.
Area of Science:
- Pediatric Neurology
- Neuroimmunology
- Demyelinating Diseases
Background:
- Acute disseminated encephalomyelitis (ADEM) is an immune-mediated inflammatory disease of the central nervous system.
- Understanding factors influencing ADEM prognosis is crucial for patient management.
- The role of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in ADEM outcomes requires further clarification.
Purpose of the Study:
- To investigate demographic, clinical, laboratory, and prognostic data in children with ADEM.
- To evaluate the association between anti-MOG antibody status and ADEM outcomes, including relapse and recovery.
- To identify clinical predictors of relapse and incomplete recovery in pediatric ADEM.
Main Methods:
- Retrospective analysis of 245 pediatric ADEM patients from 24 centers (2010-2022).
- Assessment of short- and long-term outcomes: disease severity, course, clinical relapse, and recovery rates.
- Univariant and multivariant analyses to determine predictors of outcome, with incomplete recovery defined as modified Rankin Score ≥1 or epilepsy.
Main Results:
- ADEM typically presents in early childhood (mean age 6.3 years).
- Relapse occurred in 12.6% of patients; predictors included sex, visual impairment, and ataxia.
- Incomplete recovery (23.3%) was linked to seizures and ICU admission; anti-MOG positivity showed no association with relapse or incomplete recovery.
Conclusions:
- The study supports the generally monophasic nature of ADEM with a high recovery rate in children.
- Initial clinical presentation, including specific symptoms like seizures and ataxia, can help predict ADEM outcomes.
- Anti-MOG antibody status does not appear to be a significant factor in ADEM relapse or recovery in this cohort.
Abstract:
ObjectivesTo evaluate the demographic, clinical, laboratory, and prognostic data of children with acute disseminated encephalomyelitis with respect to anti-myelin oligodendrocyte glycoprotein (MOG) antibody status.MethodsAcute disseminated encephalomyelitis patients (n = 245) from 24 centers followed up between 2010 and 2022 were evaluated retrospectively. The short- and long-term outcome characteristics (disease severity and course, clinical relapse, and recovery rates) were assessed. Incomplete clinical recovery was defined as modified Rankin Score ≥1 or the presence of epilepsy. Univariant and multivariant analysis were performed for outcome characteristics.ResultsThe mean age at diagnosis was 6.3 ± 3.8 (0.5-17.7) years and the median follow-up was 22 (3-132) months. The outcome characteristics were evaluated in 180 of 245 patients (73.4%) with at least 12 months' follow-up. Twenty-three patients (12.6%) relapsed. The multivariable logistic regression analysis revealed the following clinical parameters as predictors of relapse: sex, visual impairment, and ataxia at initial presentation. Incomplete clinical recovery (n = 42/180, 23.3%) was associated with the presence of seizures on admission and the need for an intensive care unit. Anti-MOG antibody positivity was not associated with an increased risk of relapse (25% vs 13.1%, P = .164) or incomplete clinical recovery (P = .511).ConclusionThe nationwide cohort presented further supports the typically monophasic nature of acute disseminated encephalomyelitis, and a high rate of complete recovery. The presence of certain symptoms in the acute period may assist the clinician in estimating the outcome.
More Related Videos
08:47Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
06:19Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Related Concept Videos
Rocky Mountain Spotted Fever
Arboviral Encephalitis
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Multiple Sclerosis l: Introduction